A Global Perspective on Emerging BTK Inhibitor Therapy Data for CLL and MCL

Join us virtually or in person for this live roundtable discussion held in conjunction with the 2022 ESMO Congress featuring expert perspectives on current and emerging uses of BTK inhibitors for CLL and MCL. Bring your questions for the live Q&A session with the expert panel faculty at the end of the session. Register now!

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email. Virtual attendees will receive an email with a link to join in advance of the Webinar.


Date and Time: Sunday, September 11, 2022 from 17:30 - 19:30 CET

Current and Emerging Roles for BTK Inhibitors in CLL/SLL and MCL

  • Mechanisms and efficacy of currently available BTKis
  • Development of resistance and intolerance to first- and second-generation BTKis
  • Emerging reversible noncovalent BTKis

Selecting and Sequencing BTK Inhibitor Therapy in R/R CLL/SLL and R/R MCL

Case Challenges

Clinical Pearls and Insights

  • Key abstracts from ESMO 2022


Othman Al-Sawaf, MD

Toby Eyre, MBChB, MD

Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom

This educational activity is not certified for CME/CE credit.

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners in selecting the optimal BTKi-based regimens for patients with relapsed/refractory CLL/SLL and relapsed/refractory MCL.

Target Audience
This educational program is intended for hematologists, medical oncologists, and other healthcare professionals who treat patients with CLL/SLL and MCL.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate emerging BTK inhibitor data considering the potential impact of safety and efficacy results on clinical practice
  • Plan BTKi-based therapeutic strategies for patients with R/R CLL/SLL or R/R MCL, taking into consideration global indications and recent practice-changing clinical trial results
  • Select and sequence therapy for patients with resistance to or intolerance of first-line BTKi-based therapy to optimize clinical outcomes
  • Identify patients who may be eligible for ongoing clinical trials evaluating currently available and emerging BTKis and BTKi-based combinations


This educational activity is not certified for CME/CE credit.